Abstract

A REVIEW ON CHEMISTRY, MECHANISM, CLINICAL TRIALS STUDIES OF ELAHERE (MIRVETUXIMAB SORAVTANSINE-GYNX): A NOVEL FDA APPROVED DRUG TO TREAT OVARIAN CANCER

Sana Parvez*, Kartikay Prakash and Devbrat Soni

ABSTRACT

One of the leading causes of gynaecological carcinoma-related deaths in the western world is ovarian carcinoma, which is made up of a diverse collection of neoplasms and is the eighth most prevalent carcinoma overall and the seventh most deadly malignancy affecting women globally. In the past, it has been proposed that postovulatory inclusion cysts or the ovarian surface epithelium, which arise following follicular rupture and healing, are the sources of the majority of ovarian carcinomas. ELAHERE is a newly approved drug by the Food and Drug Administration (FDA) for the treatment of ovarian cancer. The API of Elahere is Mirvetuximab Soravtansine-Gynx, used to treat adult patients who are suffering from foliate receptor Alpha (FR) positive, platinum-resistant ovarian cancer, fallopian tube cancer, or peritoneal cancer. On November 14, 2022, the FDA granted approval to the Elahere. A diagnosis device named VENTANA FOLR1 (FOLR-2.1) RxDx Assay, which is used to diagnose the above indication, was also approved by the FDA on November 14, 2022. It is an antibody-drug conjugate drug (ADC) that is directed against the FR. This study reviews all the pharmacological aspects of ELAHERE.

Keywords: Elahere, ImmunoGEN, Mirvetuximab Soravtansine-Gynx, Ovarian Cancer, Fallopian Tube, FR?.